Designing transformative clinical trials in the cancer genome era.
about
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineProspects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyIntegrating next-generation sequencing into clinical oncology: strategies, promises and pitfallsThe possibility of clinical sequencing in the management of cancerCancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers.Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.International Clinical Trials Day 2014-ancient and modern needs.Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.The translation of cancer genomics: time for a revolution in clinical cancer care.Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.Important role of translational science in rare disease innovation, discovery, and drug development.Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century.Tumour heterogeneity in the clinic.Combining targeted agents with modern radiotherapy in soft tissue sarcomas.Benchmarks for detecting 'breakthroughs' in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation.The AURORA initiative for metastatic breast cancer.The combinatorial complexity of cancer precision medicine.Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trialSubclonal diversification of primary breast cancer revealed by multiregion sequencing.Lung cancer in the era of precision medicineLung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology.Precision oncology based on omics data: The NCT Heidelberg experience.Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.Pragmatic precision oncology: the secondary uses of clinical tumor molecular profilingMechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.Application of cancer genomics to solve unmet clinical needs.Precision medicine and personalized breast cancer: combination pertuzumab therapy.Tissue-based next generation sequencing: application in a universal healthcare system.Epistatic interactions and drug response.Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.Next-generation medicines: past regulatory experience and considerations for the future.Current status of molecular biomarkers in endometrial cancer.Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.Precision therapy for lymphoma--current state and future directions.Prioritizing targets for precision cancer medicine.Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.
P2860
Q26825186-009D0DE0-3EFE-4D36-BCB7-0A12AC227F13Q27025344-6890B2D7-4D5D-48DD-A24A-53C00DA4AD0CQ28066709-A8F2B492-A433-423D-B9CA-B49CEF6447C8Q28072144-85A1D26C-5603-4DA9-BD34-9613773D6716Q30794842-39C1EA9D-9B51-4B97-AA64-3272DCF6E251Q30826387-94D3EB7E-4111-41CD-9D3C-C8DDA0B343C9Q33649540-21E6E8F5-50D8-47EB-81DF-69529292C349Q33685000-D554685A-5AFE-4AAC-A5FB-881EAB255119Q33772611-5950D8D3-3197-4D10-9425-2BC2D1146A81Q33927990-9568B848-3370-47E5-878D-65C877545150Q34011948-6AD7AC34-E693-46AE-8BE0-BC4623760D38Q34037747-C7041D45-6322-496C-8FEB-DB8868E40780Q34372080-7DCD1E3F-ADC3-4283-BBCC-D332CE576CC0Q34396047-FF4E7196-9B3A-4AB6-A2D0-7C26F92F1823Q34397235-0EB12D16-6627-4151-9177-75EBD5EADF18Q34499602-365A47B4-EE53-40A1-8571-B2F7AEDE0679Q34781332-6164D386-2FF1-4D49-ACDC-7C1EFCF21959Q35168763-09F8EEA4-0843-4DF0-9A5C-3FC989434338Q35847434-FC32F308-E4D1-4CE6-A110-7E58AB874AF6Q35861107-2556676A-76EB-4E0D-A08A-3358E16C2B5AQ36303134-C2810E0E-117B-460C-A6EA-FA5F68645B85Q36371872-358C3812-68F3-4884-BD88-164644ECC6FDQ36396606-0015EF9F-7E0E-4FB4-929A-F44554615382Q36490318-DBCFFBFD-C74A-42F2-A8E9-B64B99CB1925Q36851421-B5716FAA-62D1-4A5A-B749-7EE64EE09BB0Q37051413-D719C945-FF97-4F39-9CE0-03EDA33AB36AQ37217474-083EA4EE-CEA2-4B40-A787-D782ECBEE4CDQ37220383-B263819F-7FCD-4D81-9B62-BC61DADA6B66Q37293290-C93D9285-30A3-41C1-9E89-4155B239BEC6Q37500880-283B8623-E9A1-41AB-8C33-F03223A34F20Q37687975-43731899-AFC0-4876-AB15-D7C34C969716Q37691479-0552551E-1859-4786-9931-508A987FF720Q38150749-BFBA5147-7D04-44F7-8E2A-D78BF033CB36Q38179500-AD6E0C98-2298-41F0-BE58-0E57AB254C69Q38189221-D99094D5-5C87-4C2E-94F4-343416B18250Q38234228-454C1A52-87BA-4DFC-A489-6AE12F45D78FQ38235827-42BA1F1D-7E52-4473-9C4E-4FB72CF3EF33Q38241102-478ACDA7-A33D-4452-B5F9-3DA9F71EC18EQ38262620-BB56EDFD-C46B-4B69-B1FE-7D1DB614F8DEQ38364614-4EAF60EE-4B0A-40BC-BF1E-23EB2E4E7B83
P2860
Designing transformative clinical trials in the cancer genome era.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Designing transformative clinical trials in the cancer genome era.
@ast
Designing transformative clinical trials in the cancer genome era.
@en
Designing transformative clinical trials in the cancer genome era.
@nl
type
label
Designing transformative clinical trials in the cancer genome era.
@ast
Designing transformative clinical trials in the cancer genome era.
@en
Designing transformative clinical trials in the cancer genome era.
@nl
prefLabel
Designing transformative clinical trials in the cancer genome era.
@ast
Designing transformative clinical trials in the cancer genome era.
@en
Designing transformative clinical trials in the cancer genome era.
@nl
P2093
P356
P1476
Designing transformative clinical trials in the cancer genome era.
@en
P2093
Jan Bogaerts
Lillian L Siu
Stefan Sleijfer
P304
P356
10.1200/JCO.2012.45.3639
P407
P577
2013-04-15T00:00:00Z